Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration

被引:13
作者
Braverman, AS [1 ]
Rao, S [1 ]
Salvatti, ME [1 ]
Adamson, B [1 ]
McManus, M [1 ]
Pierre, S [1 ]
机构
[1] SUNY Hlth Sci Ctr, Downstate Coll Med, Brooklyn, NY 11203 USA
关键词
taxanes; paclitaxel; hypersensitivity; glucocorticoids;
D O I
10.1159/000085618
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Taxanes cause hypersensitivity reactions, averted by premedication with H-1 blockers and high glucocorticoid ( GC) doses. Prolonged weekly taxane administration may lead to GC toxicity. Purpose: To determine whether patients not hypersensitive to initial paclitaxel (PTX) infusion after high-dose GC premedication will tolerate subsequent, prolonged PTX treatment without GC prophylaxis. Patients and Methods: In 115/122 breast cancer patients not hypersensitive to initial PTX treatment, 20 mg dexamethasone (DXM) doses were tapered by 2.0 mg/week, reaching 0 in those receiving 9 or more courses. After 4 PTX courses, diphenhydramine was administered orally, rather than intravenously. Results: PTX was administered 143 times after 2.0 - 5.0 mg of DXM and 357 times without DXM. A total of 46 patients received 1 - 40 PTX courses without DXM. None of these 115 patients experienced hypersensitivity reactions. Conclusion: Patients unreactive to their first PTX infusions, after high-dose and tapering GC premedication, may not require GC prophylaxis for subsequent PTX therapy. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:116 / 119
页数:4
相关论文
共 17 条
[1]   Paclitaxel premedication regimens [J].
Boehm, DK ;
Maksymiuk, AW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (07) :463-465
[2]   Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions [J].
Bookman, MA ;
Kloth, DD ;
Kover, PE ;
Smolinski, S ;
Ozols, RF .
ANNALS OF ONCOLOGY, 1997, 8 (06) :611-614
[3]   Successful parenteral desensitization to paclitaxel [J].
Essayan, DM ;
KageySobotka, A ;
Colarusso, PJ ;
Lichtenstein, LM ;
Ozols, RF ;
King, ED .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (01) :42-46
[4]   Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel [J].
Gennari, A ;
Salvadori, B ;
Tognoni, A ;
Conte, PF .
ANNALS OF ONCOLOGY, 1996, 7 (09) :978-979
[5]   Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer [J].
Henderson, IC ;
Berry, DA ;
Demetri, GD ;
Cirrincione, CT ;
Goldstein, LJ ;
Martino, S ;
Ingle, JN ;
Cooper, MR ;
Hayes, DF ;
Tkaczuk, KH ;
Fleming, G ;
Holland, JF ;
Duggan, DB ;
Carpenter, JT ;
Frei, E ;
Schilsky, RL ;
Wood, WC ;
Muss, HB ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :976-983
[6]   Dose reduction of steroid premeditation for paclitaxel:: No increase of hypersensitivity reactions [J].
Köppler, H ;
Heymanns, J ;
Weide, R .
ONKOLOGIE, 2001, 24 (03) :283-285
[7]   A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel [J].
Kwon, JS ;
Elit, L ;
Finn, M ;
Hirte, H ;
Mazurka, J ;
Moens, F ;
Trim, K .
GYNECOLOGIC ONCOLOGY, 2002, 84 (03) :420-425
[8]  
LEWIS T, 2002, P AN M AM SOC CLIN, V21, pA70
[9]   Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel [J].
Leyland-Jones, B ;
Gelmon, K ;
Ayoub, JP ;
Arnold, A ;
Verma, S ;
Dias, R ;
Ghahramani, P .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3965-3971
[10]   Paclitaxel-associated hypersensitivity reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center [J].
Markman, M ;
Kennedy, A ;
Webster, K ;
Kulp, B ;
Peterson, G ;
Belinson, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :102-105